DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Down 1.9 %

Shares of NASDAQ DRRX opened at $0.95 on Friday. The firm has a fifty day simple moving average of $1.07 and a two-hundred day simple moving average of $1.30. DURECT has a 12 month low of $0.51 and a 12 month high of $1.88. The firm has a market capitalization of $29.49 million, a PE ratio of -1.56 and a beta of 1.01.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DRRX. International Assets Investment Management LLC grew its stake in shares of DURECT by 41.3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after buying an additional 6,300 shares during the last quarter. Richmond Brothers Inc. boosted its holdings in DURECT by 39.5% in the second quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after acquiring an additional 303,670 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of DURECT by 4.8% in the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after acquiring an additional 14,658 shares during the last quarter. 28.03% of the stock is owned by hedge funds and other institutional investors.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.